SCHEMBL3797948

SCHEMBL3797948

CO[C@@H]1C[C@H](S(=O)(=O)c2ccc(-c3ccc(F)cc3F)cc2C(F)(F)F)C[C@H]1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 9/20 0.37
APP P05067 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
FFAR1 O14842 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
DHFR P00374 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
LMNA P02545 1/20 0.35
TTR P02766 1/20 0.35
ALB P02768 1/20 0.35
HMGB1 P09429 1/20 0.35
HPGD P15428 1/20 0.35
CXCL12 P48061 1/20 0.35
KMT2A Q03164 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3803020 1.00 FFAR4 (0.37) FFAR4APPPDE3BPDE3AFFAR1
SCHEMBL3797334 0.89 FFAR4 (0.34) FFAR4CTSSABCB11
SCHEMBL3798425 0.89 FFAR4 (0.34) FFAR4CTSSABCB11
SCHEMBL3802265 0.87 FFAR4 (0.37) FFAR4CTSSABCB11
SCHEMBL3801684 0.87 FFAR4 (0.37) FFAR4CTSSABCB11
SCHEMBL3798932 0.84 CTSS (0.36) FFAR4LMNACTSSABCB11
SCHEMBL3798003 0.84 CTSS (0.36) FFAR4LMNACTSSABCB11
SCHEMBL1139697 0.84 CTSS (0.51) CTSS
SCHEMBL1139822 0.84 CTSS (0.51) CTSS
SCHEMBL12855877 0.84 CTSS (0.51) CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP claimed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US claimed
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP disclosed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES TBXA2R, ADORA1, CNR1 FFAR4 1618/4885APP 1507/4885PDE3B 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.